title: Cisplatin neuropathy in brain tumor chemotherapy.
abstract: 38 patients with glial brain tumors received 135 mg/m2 cisplatin intravenously every month for 5 courses. Signs and symptoms of peripheral neuropathy were evaluated clinically and electrophysiologically. This approach differs from methods previously reported in that it offers two major advantages: primary brain tumors do not cause paraneoplastic neuropathy; no neurotoxic drugs other than cisplatin were employed. Our study confirmed in this highly specific clinical model the existence of cisplatin peripheral neuropathy: we observed definite clinical signs or symptoms of neuropathy in 80% of patients receiving a cumulative cisplatin dosage of 675 mg/m2; there was a progressive dose-related decrease in SAP amplitudes, expression of a sensory axonopathy or neuronopathy.
authors.affiliation: III Divisione di Neurologia, Istituto Nazionale Neurologico C. Besta, Milano.
authors.forename: A
authors.initials: A
authors.lastname: Sghirlanzoni
authors.forename: A
authors.initials: A
authors.lastname: Silvani
authors.forename: V
authors.initials: V
authors.lastname: Scaioli
authors.forename: D
authors.initials: D
authors.lastname: Pareyson
authors.forename: R
authors.initials: R
authors.lastname: Marchesan
authors.forename: A
authors.initials: A
authors.lastname: Boiardi
mesh_terms: D000328:Adult; D001254:Astrocytoma / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D004594:Electrophysiology; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology
chemical_list: D002945:Cisplatin